Created at Source Raw Value Validated value
Dec. 16, 2020, 10:02 a.m. usa

- who 10-point clinical progression scale score > 5 (patient on non-invasive or mechanical ventilation, patient in need of high-flow oxygen therapy) - indication of transfer to intensive care unit (oxygen therapy> 8 l / min ; out or not carried out due to lata) - current treatment with nicotine replacement therapy, bupropion or varenicline in the last 30 days - known addiction problem to alcohol or other substances - contraindication for nicotine patches: - pregnant or breastfeeding woman - lack of effective contraception for women of childbearing age - generalized skin pathologies that may interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angina - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - known obliterating peripheral arterial disease - known severe heart failure with an ejection fraction <30%) - known severe renal (clcr <30 ml / min) or hepatic (child c) impairment - known pheochromocytoma - known uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or an active peptic ulcer - patient included in another interventional trial evaluating a health product - patient under guardianship or curatorship - patient deprived of liberty by judicial or administrative decision

- who 10-point clinical progression scale score > 5 (patient on non-invasive or mechanical ventilation, patient in need of high-flow oxygen therapy) - indication of transfer to intensive care unit (oxygen therapy> 8 l / min ; out or not carried out due to lata) - current treatment with nicotine replacement therapy, bupropion or varenicline in the last 30 days - known addiction problem to alcohol or other substances - contraindication for nicotine patches: - pregnant or breastfeeding woman - lack of effective contraception for women of childbearing age - generalized skin pathologies that may interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angina - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - known obliterating peripheral arterial disease - known severe heart failure with an ejection fraction <30%) - known severe renal (clcr <30 ml / min) or hepatic (child c) impairment - known pheochromocytoma - known uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or an active peptic ulcer - patient included in another interventional trial evaluating a health product - patient under guardianship or curatorship - patient deprived of liberty by judicial or administrative decision

Nov. 7, 2020, 11:31 p.m. usa

- who 10-point clinical progression scale score > 5 (patient on non-invasive or mechanical ventilation, patient in need of high-flow oxygen therapy) - indication of transfer to intensive care unit (carried out or not carried out due to lata) - current treatment with nicotine replacement therapy, bupropion or varenicline in the last 30 days - known addiction problem to alcohol or other substances - contraindication for nicotine patches: - pregnant or breastfeeding woman - lack of effective contraception for women of childbearing age - generalized skin pathologies that may interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angina - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - known obliterating peripheral arterial disease - known severe heart failure with an ejection fraction <30%) - known severe renal (clcr <30 ml / min) or hepatic (child c) impairment - known pheochromocytoma - known uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or an active peptic ulcer - patient included in another interventional trial evaluating a health product - patient under guardianship or curatorship - patient deprived of liberty by judicial or administrative decision

- who 10-point clinical progression scale score > 5 (patient on non-invasive or mechanical ventilation, patient in need of high-flow oxygen therapy) - indication of transfer to intensive care unit (carried out or not carried out due to lata) - current treatment with nicotine replacement therapy, bupropion or varenicline in the last 30 days - known addiction problem to alcohol or other substances - contraindication for nicotine patches: - pregnant or breastfeeding woman - lack of effective contraception for women of childbearing age - generalized skin pathologies that may interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angina - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - known obliterating peripheral arterial disease - known severe heart failure with an ejection fraction <30%) - known severe renal (clcr <30 ml / min) or hepatic (child c) impairment - known pheochromocytoma - known uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or an active peptic ulcer - patient included in another interventional trial evaluating a health product - patient under guardianship or curatorship - patient deprived of liberty by judicial or administrative decision

Oct. 30, 2020, 11:31 p.m. usa

- indication of transfer to intensive care unit (carried out or not carried out due to lata) - ongoing treatment with nicotine substitutes, bupropion or varenicline - known addiction problem to alcohol or other substances - contraindication for nicotine patches: - pregnant or breastfeeding woman - lack of effective contraception for women of childbearing age - generalized skin pathologies that may interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angina - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - known obliterating peripheral arterial disease - known severe heart failure with an ejection fraction <30%) - known severe renal (clcr <30 ml / min) or hepatic (child c) impairment - known pheochromocytoma - known uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or an active peptic ulcer - patient included in another interventional trial evaluating a health product - patient under guardianship or curatorship - patient deprived of liberty by judicial or administrative decision

- indication of transfer to intensive care unit (carried out or not carried out due to lata) - ongoing treatment with nicotine substitutes, bupropion or varenicline - known addiction problem to alcohol or other substances - contraindication for nicotine patches: - pregnant or breastfeeding woman - lack of effective contraception for women of childbearing age - generalized skin pathologies that may interfere with the use of a transdermal patch - stroke or myocardial infarction or acute coronary syndrome for less than 3 months - allergy to nicotine or to one of the excipients of the transdermal patch - uncontrolled high blood pressure - unstable or worsening angina - severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator) - known obliterating peripheral arterial disease - known severe heart failure with an ejection fraction <30%) - known severe renal (clcr <30 ml / min) or hepatic (child c) impairment - known pheochromocytoma - known uncontrolled hyperthyroidism - esophagitis due to gastroesophageal reflux disease or an active peptic ulcer - patient included in another interventional trial evaluating a health product - patient under guardianship or curatorship - patient deprived of liberty by judicial or administrative decision